1. Home
  2. VRCA
  3. VRCA News

Latest Verrica Pharmaceuticals Inc. (VRCA) News on July 7, 2025

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA): Are Analysts Optimistic?
VRCA

Simply Wall St.

24 days ago

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA): Are Analysts Optimistic?

Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York
VRCA

GlobeNewswire

a month ago

Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York

VRCA

Thomson Reuters StreetEvents

2 months ago

Q1 2025 Verrica Pharmaceuticals Inc Earnings Call

Verrica Pharmaceuticals Inc (VRCA) Q1 2025 Earnings Call Highlights: Strong YCANTH Demand and ...
VRCA

GuruFocus.com

2 months ago

Verrica Pharmaceuticals Inc (VRCA) Q1 2025 Earnings Call Highlights: Strong YCANTH Demand and ...

Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates
VRCA

Zacks

2 months ago

Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates

Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results
VRCA

GlobeNewswire

2 months ago

Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results

Assertio (ASRT) Reports Q1 Loss, Misses Revenue Estimates
VRCA

Zacks

2 months ago

Assertio (ASRT) Reports Q1 Loss, Misses Revenue Estimates

Earnings To Watch: Verrica Pharmaceuticals Inc (VRCA) Reports Q1 2025 Result
VRCA

GuruFocus.com

2 months ago

Earnings To Watch: Verrica Pharmaceuticals Inc (VRCA) Reports Q1 2025 Result

Verrica Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 13, 2025
VRCA

GlobeNewswire

2 months ago

Verrica Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 13, 2025

Verrica Pharmaceuticals to Participate in the Citizens Life Sciences Conference in New York
VRCA

GlobeNewswire

2 months ago

Verrica Pharmaceuticals to Participate in the Citizens Life Sciences Conference in New York

Verrica Pharmaceuticals Reports Strong Demand-Led Growth in YCANTH® Dispensed Applicator Units in First Quarter 2025
VRCA

GlobeNewswire

3 months ago

Verrica Pharmaceuticals Reports Strong Demand-Led Growth in YCANTH® Dispensed Applicator Units in First Quarter 2025

Verrica Pharmaceuticals Appoints Gavin Corcoran, M.D. to its Board of Directors
VRCA

GlobeNewswire

3 months ago

Verrica Pharmaceuticals Appoints Gavin Corcoran, M.D. to its Board of Directors

Here's Why Verrica Pharmaceuticals (VRCA) Is a Great 'Buy the Bottom' Stock Now
VRCA

Zacks

3 months ago

Here's Why Verrica Pharmaceuticals (VRCA) Is a Great 'Buy the Bottom' Stock Now

Verrica Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference
VRCA

GlobeNewswire

3 months ago

Verrica Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference

Verrica Pharmaceuticals Appoints Noah L. Rosenberg, M.D., as Chief Medical Officer
VRCA

GlobeNewswire

3 months ago

Verrica Pharmaceuticals Appoints Noah L. Rosenberg, M.D., as Chief Medical Officer

VRCA

Thomson Reuters StreetEvents

4 months ago

Q4 2024 Verrica Pharmaceuticals Inc Earnings Call

Verrica Pharmaceuticals Inc (VRCA) Q4 2024 Earnings Call Highlights: Revenue Growth and ...
VRCA

GuruFocus.com

4 months ago

Verrica Pharmaceuticals Inc (VRCA) Q4 2024 Earnings Call Highlights: Revenue Growth and ...

Verrica Pharmaceuticals Inc. (VRCA) Reports Q4 Loss, Lags Revenue Estimates
VRCA

Zacks

4 months ago

Verrica Pharmaceuticals Inc. (VRCA) Reports Q4 Loss, Lags Revenue Estimates

Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results
VRCA

GlobeNewswire

4 months ago

Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 11, 2025
VRCA

GlobeNewswire

4 months ago

Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 11, 2025

Verrica Pharmaceuticals Inc. (VRCA) Expected to Beat Earnings Estimates: Should You Buy?
VRCA

Zacks

4 months ago

Verrica Pharmaceuticals Inc. (VRCA) Expected to Beat Earnings Estimates: Should You Buy?

Verrica Pharmaceuticals to Participate in the TD Cowen 45th Annual Health Care Conference in Boston
VRCA

GlobeNewswire

4 months ago

Verrica Pharmaceuticals to Participate in the TD Cowen 45th Annual Health Care Conference in Boston

Verrica Pharmaceuticals Announces Presentation of Three Posters Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2025 Winter Clinical Dermatology Conference
VRCA

GlobeNewswire

6 months ago

Verrica Pharmaceuticals Announces Presentation of Three Posters Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2025 Winter Clinical Dermatology Conference

Verrica Provides Business and Operational Update
VRCA

GlobeNewswire

7 months ago

Verrica Provides Business and Operational Update

Verrica Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
VRCA

GlobeNewswire

7 months ago

Verrica Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

VRCA

MT Newswires

7 months ago

Verrica Pharmaceuticals' Partner Torii Seeks Japan Approval for Skin Infection Treatment

Verrica Pharmaceuticals Announces that Development Partner Torii Pharmaceutical Files New Drug Application of TO-208 the Treatment of Molluscum Contagiosum in Japan
VRCA

GlobeNewswire

7 months ago

Verrica Pharmaceuticals Announces that Development Partner Torii Pharmaceutical Files New Drug Application of TO-208 the Treatment of Molluscum Contagiosum in Japan

Verrica Announces Pricing of $42.0 Million Public Offering
VRCA

GlobeNewswire

8 months ago

Verrica Announces Pricing of $42.0 Million Public Offering

Verrica Announces Proposed Public Offering
VRCA

GlobeNewswire

8 months ago

Verrica Announces Proposed Public Offering

Verrica Pharmaceuticals Reports Third Quarter 2024 Financial Results and Announces Leadership Transition
VRCA

GlobeNewswire

8 months ago

Verrica Pharmaceuticals Reports Third Quarter 2024 Financial Results and Announces Leadership Transition

Verrica Pharmaceuticals Announces Acceptance of Two Abstracts Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2024 Fall Clinical Dermatology Conference
VRCA

GlobeNewswire

8 months ago

Verrica Pharmaceuticals Announces Acceptance of Two Abstracts Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2024 Fall Clinical Dermatology Conference

Verrica Pharmaceuticals Inc (VRCA) Q2 2024 Earnings Call Highlights: Revenue Growth Amid Rising ...
VRCA

GuruFocus.com

9 months ago

Verrica Pharmaceuticals Inc (VRCA) Q2 2024 Earnings Call Highlights: Revenue Growth Amid Rising ...

VRCA

MT Newswires

9 months ago

RBC Lowers Price Target on Verrica Pharmaceuticals to $11 From $13, Keeps Outperform, Speculative Risk

VRCA

MT Newswires

9 months ago

Sector Update: Health Care Stocks Softer Wednesday Afternoon

VRCA

MT Newswires

9 months ago

Verrica Pharmaceuticals to Restructure Sales, Operating Teams; Cut Sales Territories

Verrica Pharmaceuticals Announces Restructuring of Commercial Organization
VRCA

GlobeNewswire

9 months ago

Verrica Pharmaceuticals Announces Restructuring of Commercial Organization

Verrica Pharmaceuticals Inc. (VRCA): Worst 52-Week Low Stock to Buy Now
VRCA

Insider Monkey

9 months ago

Verrica Pharmaceuticals Inc. (VRCA): Worst 52-Week Low Stock to Buy Now

Is Verrica Pharmaceuticals Inc. (VRCA) The Worst 52-Week Low Stocks to Buy Now According to Short Sellers?
VRCA

Insider Monkey

9 months ago

Is Verrica Pharmaceuticals Inc. (VRCA) The Worst 52-Week Low Stocks to Buy Now According to Short Sellers?

Verrica Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York
VRCA

GlobeNewswire

10 months ago

Verrica Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York

When Will Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Turn A Profit?
VRCA

Simply Wall St.

10 months ago

When Will Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Turn A Profit?

VRCA

MT Newswires

a year ago

RBC Adjusts Price Target on Verrica Pharmaceuticals to $13 From $14, Maintains Outperform

Verrica stock drops after half patients’ tumours gone in skin cancer trial
VRCA

Clinical Trials Arena

a year ago

Verrica stock drops after half patients’ tumours gone in skin cancer trial

VRCA

MT Newswires

a year ago

Top Midday Decliners

Why Is Dermatology-Focused Verrica Pharmaceuticals Stock Trading Lower On Wednesday?
VRCA

Benzinga

a year ago

Why Is Dermatology-Focused Verrica Pharmaceuticals Stock Trading Lower On Wednesday?

VRCA

MT Newswires

a year ago

Sector Update: Health Care Stocks Edge Higher Premarket Wednesday

Verrica Pharmaceuticals Inc. (VRCA) Reports Q2 Loss, Tops Revenue Estimates
VRCA

Zacks

a year ago

Verrica Pharmaceuticals Inc. (VRCA) Reports Q2 Loss, Tops Revenue Estimates

VRCA

MT Newswires

a year ago

Verrica Pharmaceuticals' Shares Surge 26% Pre-Bell on Data From Study of VP-315 to Treat Basal Cell Carcinoma

Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results
VRCA

GlobeNewswire

a year ago

Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results

Verrica Pharmaceuticals Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of VP-315, an Investigational Oncolytic Peptide-Based Immunotherapy for the Treatment of Patients with Basal Cell Carcinoma
VRCA

GlobeNewswire

a year ago

Verrica Pharmaceuticals Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of VP-315, an Investigational Oncolytic Peptide-Based Immunotherapy for the Treatment of Patients with Basal Cell Carcinoma

Verrica Pharmaceuticals to Report Second Quarter Financial Results and Release Preliminary Topline Results from Part 2 of Phase 2 Trial of VP-315 for the Treatment of Basal Cell Carcinoma on August 14, 2024
VRCA

GlobeNewswire

a year ago

Verrica Pharmaceuticals to Report Second Quarter Financial Results and Release Preliminary Topline Results from Part 2 of Phase 2 Trial of VP-315 for the Treatment of Basal Cell Carcinoma on August 14, 2024

3 High Insider Ownership US Stocks With Up To 52% Revenue Growth
VRCA

Simply Wall St.

a year ago

3 High Insider Ownership US Stocks With Up To 52% Revenue Growth

Zevra Therapeutics (ZVRA) Surges 21.9%: Is This an Indication of Further Gains?
VRCA

Zacks

a year ago

Zevra Therapeutics (ZVRA) Surges 21.9%: Is This an Indication of Further Gains?

VRCA

MT Newswires

a year ago

Verrica Pharmaceuticals Settles Cantharidin-Related Lawsuit With Dormer Labs

Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories, Inc.
VRCA

GlobeNewswire

a year ago

Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories, Inc.

High Insider Ownership Growth Stocks On US Exchange For June 2024
VRCA

Simply Wall St.

a year ago

High Insider Ownership Growth Stocks On US Exchange For June 2024

Recent 12% pullback would hurt Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) insiders
VRCA

Simply Wall St.

a year ago

Recent 12% pullback would hurt Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) insiders

Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York
VRCA

GlobeNewswire

a year ago

Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York

High Insider Ownership Growth Companies On US Exchange May 2024
VRCA

Simply Wall St.

a year ago

High Insider Ownership Growth Companies On US Exchange May 2024

VRCA

MT Newswires

a year ago

Verrica Pharmaceuticals Amends Licensing Agreement With Torii Pharmaceutical for Phase 3 Trial of Ycanth

Verrica Pharmaceuticals Announces Amendment to Company’s Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts
VRCA

GlobeNewswire

a year ago

Verrica Pharmaceuticals Announces Amendment to Company’s Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts

VRCA

MT Newswires

a year ago

HC Wainwright Adjusts Price Target on Verrica Pharmaceuticals to $14 From $13, Maintains Buy Rating

VRCA

MT Newswires

a year ago

Needham Adjusts Price Target on Verrica Pharmaceuticals to $16 From $8, Keeps Buy Rating

VRCA

GuruFocus.com

a year ago

Verrica Pharmaceuticals Inc (VRCA) Q1 2024 Earnings Call Transcript Highlights: Strategic ...

Verrica Pharmaceuticals Inc (VRCA) Reports Q1 2024 Results: A Detailed Financial Review
VRCA

GuruFocus.com

a year ago

Verrica Pharmaceuticals Inc (VRCA) Reports Q1 2024 Results: A Detailed Financial Review

Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates
VRCA

Zacks

a year ago

Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates

Verrica Pharmaceuticals Reports First Quarter 2024 Financial Results
VRCA

GlobeNewswire

a year ago

Verrica Pharmaceuticals Reports First Quarter 2024 Financial Results

Verrica Pharmaceuticals to Present at Upcoming Investor Conferences
VRCA

GlobeNewswire

a year ago

Verrica Pharmaceuticals to Present at Upcoming Investor Conferences

Verrica Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 13, 2024
VRCA

GlobeNewswire

a year ago

Verrica Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 13, 2024

Verrica Pharmaceuticals (VRCA) Moves 7.4% Higher: Will This Strength Last?
VRCA

Zacks

a year ago

Verrica Pharmaceuticals (VRCA) Moves 7.4% Higher: Will This Strength Last?

Strength Seen in Amneal (AMRX): Can Its 12.0% Jump Turn into More Strength?
VRCA

Zacks

a year ago

Strength Seen in Amneal (AMRX): Can Its 12.0% Jump Turn into More Strength?

Strong week for Verrica Pharmaceuticals (NASDAQ:VRCA) shareholders doesn't alleviate pain of three-year loss
VRCA

Simply Wall St.

a year ago

Strong week for Verrica Pharmaceuticals (NASDAQ:VRCA) shareholders doesn't alleviate pain of three-year loss

Verrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference
VRCA

GlobeNewswire

a year ago

Verrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference

Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDA
VRCA

GlobeNewswire

a year ago

Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDA

When Will Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Become Profitable?
VRCA

Simply Wall St.

a year ago

When Will Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Become Profitable?

Verrica Pharmaceuticals Full Year 2023 Earnings: Revenues Beat Expectations, EPS In Line
VRCA

Simply Wall St.

a year ago

Verrica Pharmaceuticals Full Year 2023 Earnings: Revenues Beat Expectations, EPS In Line

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q4 2023 Earnings Call Transcript
VRCA

Insider Monkey

a year ago

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q4 2023 Earnings Call Transcript

VRCA

GuruFocus.com

a year ago

Verrica Pharmaceuticals Inc (VRCA) Reports Fourth Quarter and Full-Year 2023 Financial Results

Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results
VRCA

GlobeNewswire

a year ago

Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results

Verrica Pharmaceuticals Announces Participation in the TD Cowen 44th Annual Healthcare Conference
VRCA

GlobeNewswire

a year ago

Verrica Pharmaceuticals Announces Participation in the TD Cowen 44th Annual Healthcare Conference

Verrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024
VRCA

GlobeNewswire

a year ago

Verrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024

Verrica Pharmaceuticals Files Lawsuit Against Canadian Drug Manufacturer for False Advertising and Unfair Competition
VRCA

GlobeNewswire

a year ago

Verrica Pharmaceuticals Files Lawsuit Against Canadian Drug Manufacturer for False Advertising and Unfair Competition

Verrica Pharmaceuticals Receives Permanent J-Code (J7354) for YCANTH™ from Centers for Medicare and Medicaid Services
VRCA

GlobeNewswire

a year ago

Verrica Pharmaceuticals Receives Permanent J-Code (J7354) for YCANTH™ from Centers for Medicare and Medicaid Services

HS2 bosses in talks to scrap first-class seats to maintain passenger capacity
VRCA

The Telegraph

a year ago

HS2 bosses in talks to scrap first-class seats to maintain passenger capacity

Bridgewater Bancshares, Inc. (NASDAQ:BWB) Full-Year Results Just Came Out: Here's What Analysts Are Forecasting For This Year
VRCA

Simply Wall St.

a year ago

Bridgewater Bancshares, Inc. (NASDAQ:BWB) Full-Year Results Just Came Out: Here's What Analysts Are Forecasting For This Year

EPIX: Updated Data for Phase 1 Trial of Masofaniten Shows 63% of Patients Achieved PSA <0.2 ng/mL…
VRCA

Zacks Small Cap Research

a year ago

EPIX: Updated Data for Phase 1 Trial of Masofaniten Shows 63% of Patients Achieved PSA <0.2 ng/mL…

LexinFintech Holdings Ltd.'s (NASDAQ:LX) most bullish insider is CEO Wenjie Xiao, and their holdings value went up by 14% last week
VRCA

Simply Wall St.

a year ago

LexinFintech Holdings Ltd.'s (NASDAQ:LX) most bullish insider is CEO Wenjie Xiao, and their holdings value went up by 14% last week

Obsidian Energy Announces 2024 Guidance With 12 Percent Growth in Average Annual Production to 36,000 boe/d
VRCA

Newsfile

a year ago

Obsidian Energy Announces 2024 Guidance With 12 Percent Growth in Average Annual Production to 36,000 boe/d

VRCA

Associated Press Finance

a year ago

Northfield: Q4 Earnings Snapshot

Northfield Bancorp, Inc. Announces the Appointment of Dr. Rachana A. Kulkarni to Its Board of Directors
VRCA

GlobeNewswire

a year ago

Northfield Bancorp, Inc. Announces the Appointment of Dr. Rachana A. Kulkarni to Its Board of Directors

TotalEnergies (TTE) Eyes March Restart for Denmark's Tyra Field
VRCA

Zacks

a year ago

TotalEnergies (TTE) Eyes March Restart for Denmark's Tyra Field

7 Potential Short-Squeeze Stocks Poised for Rapid Gains
VRCA

InvestorPlace

a year ago

7 Potential Short-Squeeze Stocks Poised for Rapid Gains

3 Promising Blockchain Stocks to Buy to Become a Crypto Millionaire
VRCA

InvestorPlace

a year ago

3 Promising Blockchain Stocks to Buy to Become a Crypto Millionaire

GrafTech Announces Fourth Quarter and Full Year 2023 Earnings Conference Call and Webcast
VRCA

Business Wire

a year ago

GrafTech Announces Fourth Quarter and Full Year 2023 Earnings Conference Call and Webcast

VRCA

Business Wire

a year ago

Western Asset High Income Fund II Inc. Authorizes Rights Offering

Natural Grocers by Vitamin Cottage (NYSE:NGVC) Has Some Way To Go To Become A Multi-Bagger
VRCA

Simply Wall St.

a year ago

Natural Grocers by Vitamin Cottage (NYSE:NGVC) Has Some Way To Go To Become A Multi-Bagger

VRCA

Business Wire

a year ago

Putnam Investments Announces 19(a) Notices for Closed-End Municipal Funds

Tejon Ranch Company to Start Construction on Its First Residential Multi-Family Community, Terra Vista at Tejon
VRCA

GlobeNewswire

a year ago

Tejon Ranch Company to Start Construction on Its First Residential Multi-Family Community, Terra Vista at Tejon

i-80 Provides 2023 Summary & 2024 Plans - Highlighting Numerous Achievements & Catalysts
VRCA

PR Newswire

a year ago

i-80 Provides 2023 Summary & 2024 Plans - Highlighting Numerous Achievements & Catalysts

New Mountain Finance Corporation Schedules its Fourth Quarter and Year Ended December 31, 2023 Earnings Release and Conference Call
VRCA

Business Wire

2 years ago

New Mountain Finance Corporation Schedules its Fourth Quarter and Year Ended December 31, 2023 Earnings Release and Conference Call

Verrica Pharmaceuticals Announces Last Patient Dosed in Part 2 of Phase 2 Study of VP-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma
VRCA

GlobeNewswire

2 years ago

Verrica Pharmaceuticals Announces Last Patient Dosed in Part 2 of Phase 2 Study of VP-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma

Share on Social Networks: